AffaMed Therapeutics has announced that the US FDA has cleared its Investigational New Drug (IND) application for the clinical development of AM712 (ASKG712), a novel proprietary bispecific biologic molecule blocking both vascular endothelial growth factor...
Novartis has scaled up manufacturing of wet age-related macular degeneration (AMD) monoclonal antibody RTH258 ahead of a potential regulatory submission next year.
Roslin Cells has signed a contract with Neusentis, a research unit of Pfizer based in Cambridge, UK, to support the manufacture of retinal pigment epithelium (RPE) cells to be used in a cell therapy clinical trial.
Recent reports of a 'clinical trial' assessing 'stem cells' for the treatment of AMD are wrong say the Japanese researchers trying to transform somatic cells into retinal pigment epithelium (RPE) cells for transplant.
Scientists at the University of British Columbia have pioneered a magnetic retinal implant that can supply a regulated and on-demand release of drugs to treat blindness from diabetic retinopathy.
Belgium-based biopharmaceutical company, ThromboGenics, has signed a ten-year supply agreement with MSD Biologics, to produce microplasmin for the treatment of retinal disorders.
